Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Anti-TNF Therapy Plus Methotrexate, Combination Therapy of DMARDs, and Methotrexate Alone in Very Early Polyarticular Juvenile Idiopathic Arthritis. A National Randomized Multicenter Clinical Trial.
Brief Summary: The objective of this study is to compare in very early polyarticular juvenile idiopathic arthritis (JIA) the efficacy, safety, and cost-benefit-ratio of three treatment strategies: biologic combination, combination of conventional disease-modifying drugs (DMARDs), and methotrexate alone.


Options:
A: Arm Label: Double-Blind Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX | Arm Label: Double-Blind Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: Double-Blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Double-Blind Adalimumab/Placebo | Arm Label: OLE BSA Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE BSA Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE BSA Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Arm Label: OLE FD Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: OLE FD Adalimumab +/- MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo + MTX; Assigned to Arm(s): Double-Blind Adalimumab + MTX, Double-Blind Placebo + MTX | Intervention Type: BIOLOGICAL; Name: Double-Blind Adalimumab/Placebo; Assigned to Arm(s): Double-Blind Adalimumab, Double-Blind Placebo | Intervention Type: DRUG; Name: OLE BSA Adalimumab +/- MTX; Assigned to Arm(s): OLE BSA Adalimumab, OLE BSA Adalimumab + MTX | Intervention Type: DRUG; Name: OLE FD Adalimumab +/- MTX; Assigned to Arm(s): OLE FD Adalimumab, OLE FD Adalimumab + MTX
B: Arm Label: Continue adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Stop adalimumab; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Continue adalimumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Stop adalimumab
C: Arm Label: Infliximab plus Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Infliximab plus methotrexate | Arm Label: Combination of DMARDs; Type: EXPERIMENTAL; Interventions: Drug: Combination of DMARDs | Arm Label: Methotrexate alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate alone | Intervention Type: DRUG; Name: Infliximab plus methotrexate; Assigned to Arm(s): Infliximab plus Methotrexate | Intervention Type: DRUG; Name: Combination of DMARDs; Assigned to Arm(s): Combination of DMARDs | Intervention Type: DRUG; Name: Methotrexate alone; Assigned to Arm(s): Methotrexate alone
D: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Anti-tumor necrosis factor alpha monoclonal antibody | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Anti-tumor necrosis factor alpha monoclonal antibody; Assigned to Arm(s): adalimumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: C